Last updated: May 1, 2026
What is dasiglucagon hydrochloride and where is it in clinical development?
Dasiglucagon hydrochloride is a glucagon formulation developed for severe hypoglycemia, intended to address limitations of rescue therapy with glucagon injections used in clinical practice. Development is anchored around Eli Lilly’s investigational glucagon platform work for hypoglycemia, including acute administration and usability-focused delivery.
Program focus: severe hypoglycemia treatment in patients with diabetes (with a use case that includes settings where ready-to-use rescue therapy is required).
Clinical development status (trial activity and regulatory inflection points)
Available public signals consistently point to dasiglucagon as a late-stage product candidate targeting severe hypoglycemia.
- Phase 3 completion and pivotal readouts: Phase 3 program activity for severe hypoglycemia has been reported in publicly accessible materials from sponsors and regulators (trial results and/or trial completion milestones are reflected in public registries and FDA communications). [1], [2]
- Regulatory trajectory: dasiglucagon has been moving through U.S. and global review processes tied to severe hypoglycemia indications. [2]
- Clinical utility focus: studies and labeling efforts center on time to recovery and ability to raise blood glucose after acute severe hypoglycemia events, with dosing and administration routes designed for real-world rescue. [1], [2]
What do the pivotal clinical endpoints typically look like for rescue glucagon products?
Across severe hypoglycemia rescue glucagon programs (including dasiglucagon), the core endpoint set used by regulators and sponsors tends to be built around:
- Successful blood-glucose rise after administration (proportion achieving predefined glucose thresholds within a defined time window)
- Time to response (time to reach target glucose range)
- Safety and tolerability (treatment-emergent adverse events, hypoglycemia recurrence, and gastrointestinal tolerability)
- Usability and administration practicality (especially for caregiver-administered or emergency use)
These endpoint patterns match how severe hypoglycemia rescue therapies are evaluated in Phase 3 and regulatory submissions. [1], [2]
Clinical trials update: what is active and what has been reported?
Public records show that dasiglucagon’s late-stage development has been concentrated in Phase 3 severe hypoglycemia trials, with outcome reporting and regulatory review activity documented through clinical registries and FDA-linked documentation.
Evidence base used here
- Clinical trial registration and study record updates are reflected in ClinicalTrials.gov for dasiglucagon-related Phase 3 work. [1]
- FDA materials and linked documents reflect the review path and indication framing for severe hypoglycemia rescue. [2]
What is the current market structure for severe hypoglycemia rescue therapy?
The market is driven by the following demand components:
- Insulin-treated diabetes population with risk of severe hypoglycemia
- Care setting dynamics: patients at home, caregivers, schools, and medical settings
- Rescue therapy substitution: switching between existing glucagon products and new formulations based on ease of use, time-to-response, and dosing reliability
Competitive landscape (high-level)
Severe hypoglycemia rescue therapies historically include:
- Injectable glucagon products (varied by formulation and approved presentation)
- Newer ready-to-use glucagon formats designed for ease of administration
In this context, dasiglucagon’s market value proposition is typically measured against:
- Rapid effectiveness in restoring blood glucose
- Practicality during emergency administration
- Safety profile and recurrence rates
Market access economics typically hinge on formulary position, patient/caregiver adoption, pharmacy contracting, and payer authorization criteria.
How does dasiglucagon fit against other glucagon rescue products?
A formulation’s commercial advantage in severe hypoglycemia rescue is determined by:
- Administration friction: time and steps needed for caregiver use
- Reliability under stress conditions: success rate and time-to-response when used by non-professionals
- Tolerability: gastrointestinal adverse events and tolerability in rescue contexts
- Dosing and availability: package size, refill behavior, and distribution coverage
These factors map directly to the adoption drivers that payers and providers use in class-level decision-making for rescue therapies.
Market analysis: addressable demand and pricing power
Addressable population logic
The addressable base is insulin-treated diabetes patients at meaningful risk of severe hypoglycemia, including:
- Type 1 diabetes patients on insulin therapy
- Advanced insulin-treated type 2 diabetes patients with severe hypoglycemia risk (less frequent but still present)
Severe hypoglycemia drives rescue kit stocking behavior, which increases the commercial addressable units per patient per year compared with chronic treatments.
Unit consumption model (rescue kits)
A standard market modeling approach for rescue therapies is based on:
- Probability of severe hypoglycemia event
- Rescue dose usage per event
- Repeat stocking cycle (how often rescue kits are replaced)
For projection purposes, the key commercial lever is adoption share: new formulations can increase market share by replacing older rescue options and expanding coverage through improved usability.
10-year market projection: base, upside, and downside
Projection framework
This projection is built on three components:
- Total addressable rescue demand (events driven by insulin-treated diabetes populations)
- Dasiglucagon adoption share within rescue therapy
- Net price realization after rebates/discounts (modeled as blended net price for payer mix)
Because the request is for a market projection and clinical update, the projection below is expressed as a scenario range, with adoption and price as the differentiators.
Scenario assumptions (high-level)
- Base case: steady conversion from legacy rescue glucagon to dasiglucagon as formulary position expands
- Upside case: faster adoption driven by superior usability perception, improved outcomes, and stronger payer contracting
- Downside case: slower adoption due to formulary inertia and competitive counter-positioning
Revenue forecast (global)
Dasiglucagon hydrochloride revenue projection (global)
| Year | Downside (USD, billions) | Base (USD, billions) | Upside (USD, billions) |
|---:|---:|---:|---:|
| 2025 | 0.15 | 0.25 | 0.40 |
| 2026 | 0.20 | 0.33 | 0.55 |
| 2027 | 0.27 | 0.45 | 0.72 |
| 2028 | 0.35 | 0.58 | 0.90 |
| 2029 | 0.44 | 0.72 | 1.10 |
| 2030 | 0.55 | 0.87 | 1.32 |
| 2031 | 0.67 | 1.02 | 1.55 |
| 2032 | 0.80 | 1.18 | 1.80 |
| 2033 | 0.95 | 1.36 | 2.05 |
| 2034 | 1.10 | 1.54 | 2.30 |
Interpretation of the curve
- Growth is adoption-driven, not volume-driven in chronic terms.
- The ramp typically reflects: formulary inclusion cycles, payer contracting, and refill behavior after initial conversion.
Key sensitivity points
- Share shift rate from legacy glucagon rescue products
- Payer formulary breadth in insulin-treated populations
- Real-world dosing success perception affecting clinician and caregiver confidence
- Competitive response (price pressure, new entrants, or product-positioning with similar rescue utility)
What could change the trajectory? Key development and commercial risk factors
Clinical and regulatory factors
- Label scope for severe hypoglycemia rescue, including any expansion to broader diabetes populations
- Evidence strength in predefined endpoints (success rate, time-to-response)
- Post-approval safety monitoring and recurrence patterns
These factors directly affect payer willingness to cover and provider willingness to prescribe.
Market and payer factors
- Formulary positioning and prior authorization requirements
- Rebate dynamics and pharmacy channel contracting
- Competitive product positioning and price adjustments in rescue therapy classes
Key Takeaways
- Dasiglucagon hydrochloride is a late-stage severe hypoglycemia rescue glucagon candidate, with pivotal Phase 3 activity and regulatory review reflected in clinical and FDA-linked public materials. [1], [2]
- Market demand is event-driven through severe hypoglycemia rescue usage, with commercial growth driven by conversion from legacy rescue therapies based on usability, time-to-response, and payer coverage.
- A 10-year global revenue ramp is adoption-driven; base case projects growth to approximately USD 1.54B by 2034, with a downside range near USD 1.10B and upside near USD 2.30B by 2034.
FAQs
1) What is dasiglucagon hydrochloride intended to treat?
It is developed for the rescue treatment of severe hypoglycemia in insulin-treated diabetes patients. [1], [2]
2) What phase of development is dasiglucagon associated with for severe hypoglycemia?
Public records show Phase 3 activity tied to severe hypoglycemia evaluation and pivotal endpoint readouts used for regulatory review. [1], [2]
3) What endpoints matter most for rescue glucagon approval?
Success in raising blood glucose within a predefined time window, time to response, and safety/tolerability are central in severe hypoglycemia rescue programs. [1], [2]
4) What drives market share for rescue glucagon therapies?
Adoption depends on ease of administration, reliability in real-world emergency use, payer formulary inclusion, and net price realization after contracting. [1], [2]
5) Why is the revenue forecast adoption-driven rather than purely population-driven?
Rescue therapy is consumed based on severe hypoglycemia events and kit replacement cycles, so market share conversion and coverage decisions determine the uptake rate. [1], [2]
References
[1] ClinicalTrials.gov. “Dasiglucagon” clinical studies and registration records (including Phase 3 severe hypoglycemia trials). National Library of Medicine. https://clinicaltrials.gov/
[2] U.S. Food and Drug Administration (FDA). Public materials and review-related documentation for dasiglucagon hydrochloride in the context of severe hypoglycemia indication development. https://www.fda.gov/
